5 unchanged sentences
All of our executive officers and other employees are at-will employees, and therefore may terminate employment with us at any time with no advance notice.
−Removed: In particular, we are highly dependent upon our management team, especially our President and Chief
−Removed: Executive Officer and the rest of our senior management.
+Added: In particular, we are highly dependent upon our management team, especially our President and Chief Executive Officer and the rest of our senior management.
The replacement of key personnel involves significant time and costs, may significantly delay or prevent the achievement of our business objectives and may harm our business.
5 unchanged sentences
We experienced some disruption within the sales organization at the time of the Chief Executive Officer transition, which led to decreased productivity and higher salesforce turnover, as well as the termination of employment of our Senior Vice President of U.S.
−Removed: We have also announced plans to hire additional leadership in medical affairs, clinical, reimbursement and sales.
+Added: Since the beginning of the second quarter of fiscal 2024, we have hired new leaders for sales, medical affairs, clinical, reimbursement and human resources, completing the expansion of the executive team.
Accordingly, our future financial performance will depend on our ability to attract, motivate, integrate and retain our senior management and employees.
5 unchanged sentences
Such litigation, whether or not meritorious, may impede our ability to attract or use executive officers and other key employees who have been employed by our competitors and may result in claims against us.
+Added: If third-party payors do not provide adequate coverage and reimbursement for the use of Barostim, our revenue will be negatively impacted.
+Added: Medicare reimbursement levels are important to increasing adoption of Barostim because nearly two-thirds of the target patient population for Barostim is over the age of 65.
+Added: On January 1, 2024, Barostim was reassigned to New Technology APC 1580, which carries an average payment amount of $45,000.
+Added: In July 2024, CMS proposed OPPS rules for 2025, including moving Barostim procedures back to APC 5465, which would reduce the average payment amount for Barostim to $31,000.
+Added: We believe the data supports creation of a Level 6 Neurostimulator APC and will work with CMS with the goal of achieving this, or alternatively, leaving Barostim in New Technology APC 1580 for another year.
+Added: Any future decline in the amount Medicare is willing to reimburse our customers for procedures using Barostim could make it difficult for new customers to adopt Barostim and could create additional pricing pressure for us, which could adversely affect our ability to invest in and grow our business.
+Added: From time to time, physicians and hospitals have in the past experienced, and others may experience, delays in Medicare reimbursement, which have delayed or may delay their willingness to schedule additional Barostim procedures.
Unregistered Sales of Equity Securities and Use of Proceeds
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.